1. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. (January 2018) Authors: de Alarcon, Pedro A; Matthay, Katherine K; London, Wendy B; Naranjo, Arlene; Tenney, Sheena C; Panzer, Jessica A; Hogarty, Michael D; Park, Julie R; Maris, John M; Cohn, Susan L Journal: Lancet Issue: Volume 2:Number 1(2018) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗